IQVIA Holdings IQV
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
IQVIA Holdings (IQV) Business Model and Operations Summary
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Key Insights
IQVIA Holdings (IQV) Core Market Data and Business Metrics
Latest Closing Price
$171.24Market Cap
$30.24 BillionPrice-Earnings Ratio
22.86Total Outstanding Shares
176.32 Million SharesTotal Employees
88,000Dividend
No dividendIPO Date
May 9, 2013SIC Description
Services-commercial Physical & Biological ResearchPrimary Exchange
New York Stock ExchangeHeadquarters
2400 Ellis Road, Durham, NC, 27703
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-1.44 Billion |
| Net Cash Flow | $326 Million |
| Net Cash Flow From Financing Activities | $-878 Million |
| Net Cash Flow From Operating Activities, Continuing | $2.72 Billion |
| Exchange Gains/Losses | $-68 Million |
| Net Cash Flow From Investing Activities | $-1.44 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Operating Income/Loss | $2.20 Billion |
| Interest Expense, Operating | $670 Million |
| Basic Earnings Per Share | $7.57 |
| Income Tax Expense/Benefit, Deferred | $-129 Million |
| Revenues | $15.40 Billion |
| Diluted Average Shares | $183.40 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $1.20 Billion |
| Other Comprehensive Income/Loss | $-171 Million |
| Comprehensive Income/Loss | $1.20 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Accounts Receivable | $3.20 Billion |
| Liabilities And Equity | $26.90 Billion |
| Wages | $905 Million |
| Prepaid Expenses | $154 Million |
| Other Current Assets | $2.47 Billion |
| Current Assets | $5.83 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||